265 related articles for article (PubMed ID: 26908733)
1. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
[TBL] [Abstract][Full Text] [Related]
3. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
[TBL] [Abstract][Full Text] [Related]
4. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.
Saffar H; Khalifeloo M; Saffar MJ; Abdollahi A; Parsaei MR; Ghorbani GR; Salarvand S; Aarabi M
BMC Infect Dis; 2021 Mar; 21(1):305. PubMed ID: 33765968
[TBL] [Abstract][Full Text] [Related]
5. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
6. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
7. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.
Böttiger M; Christenson B; Romanus V; Taranger J; Strandell A
Br Med J (Clin Res Ed); 1987 Nov; 295(6608):1264-7. PubMed ID: 3120971
[TBL] [Abstract][Full Text] [Related]
8. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
9. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children.
Hiltunen M; Hyöty H; Leinikki P; Akerblom HK; Tuomilehto J; Vesikari T
Diabet Med; 1994 Dec; 11(10):942-6. PubMed ID: 7895458
[TBL] [Abstract][Full Text] [Related]
10. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
11. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
Davidkin I; Valle M; Julkunen I
Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851
[TBL] [Abstract][Full Text] [Related]
12. Application of a fast and cost-effective 'three-in-one' MMR ELISA as a tool for surveying anti-MMR humoral immunity: the Hungarian experience.
Böröcz K; Csizmadia Z; Markovics Á; Farkas N; Najbauer J; Berki T; Németh P
Epidemiol Infect; 2020 Feb; 148():e17. PubMed ID: 32014073
[TBL] [Abstract][Full Text] [Related]
13. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine].
Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L
Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334
[TBL] [Abstract][Full Text] [Related]
14. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD
Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446
[TBL] [Abstract][Full Text] [Related]
16. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
Johnson H; Hillary IB; McQuoid G; Gilmer BA
Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
[TBL] [Abstract][Full Text] [Related]
17. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.
Christenson B; Böttiger M
Vaccine; 1994 Feb; 12(2):129-33. PubMed ID: 8147093
[TBL] [Abstract][Full Text] [Related]
18. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
[TBL] [Abstract][Full Text] [Related]
19. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.
Peltola H; Karanko V; Kurki T; Hukkanen V; Virtanen M; Penttinen K; Nissinen M; Heinonen OP
Lancet; 1986 Jan; 1(8473):137-9. PubMed ID: 2867355
[TBL] [Abstract][Full Text] [Related]
20. Response to third rubella vaccine dose.
Siira L; Nøkleby H; Barlinn R; Riise ØR; Aaberge IS; Dudman SG
Hum Vaccin Immunother; 2018; 14(10):2472-2477. PubMed ID: 29771601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
